Sichuan Huiyu Pharmaceutical Co Ltd
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levet… Read more
Sichuan Huiyu Pharmaceutical Co Ltd (688553) - Net Assets
Latest net assets as of September 2025: CN¥3.72 Billion CNY
Based on the latest financial reports, Sichuan Huiyu Pharmaceutical Co Ltd (688553) has net assets worth CN¥3.72 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.88 Billion) and total liabilities (CN¥1.16 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.72 Billion |
| % of Total Assets | 76.31% |
| Annual Growth Rate | N/A |
| 5-Year Change | 428.74% |
| 10-Year Change | N/A |
| Growth Volatility | 143.3 |
Sichuan Huiyu Pharmaceutical Co Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Sichuan Huiyu Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sichuan Huiyu Pharmaceutical Co Ltd (2017–2024)
The table below shows the annual net assets of Sichuan Huiyu Pharmaceutical Co Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.97 Billion | +5.27% |
| 2023-12-31 | CN¥3.77 Billion | +1.52% |
| 2022-12-31 | CN¥3.72 Billion | +4.48% |
| 2021-12-31 | CN¥3.56 Billion | +373.53% |
| 2020-12-31 | CN¥751.48 Million | +83.90% |
| 2019-12-31 | CN¥408.65 Million | +371.16% |
| 2018-12-31 | CN¥-150.70 Million | +18.68% |
| 2017-12-31 | CN¥-185.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sichuan Huiyu Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 124148077733.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥953.61 Million | 23.97% |
| Common Stock | CN¥423.60 Million | 10.65% |
| Other Components | CN¥2.60 Billion | 65.39% |
| Total Equity | CN¥3.98 Billion | 100.00% |
Sichuan Huiyu Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Sichuan Huiyu Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TOWA PHARMA. CO.
F:6QC
|
$514.92 Million |
|
Hwang Chang General Contractor Co Ltd
TW:2543
|
$514.98 Million |
|
Ningbo Donly Co Ltd
SHE:002164
|
$515.03 Million |
|
Malion New Materials Co Ltd
SHE:300586
|
$515.18 Million |
|
ICOSF
PINK:ICOSF
|
$514.68 Million |
|
Luolai Home Textile Co Ltd
SHE:002293
|
$514.67 Million |
|
Changzhou Tenglong Auto Parts
SHG:603158
|
$514.23 Million |
|
Nan Pao Resins Chemical Co Ltd
TW:4766
|
$514.20 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sichuan Huiyu Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,770,594,432 to 3,979,044,445, a change of 208,450,013 (5.5%).
- Net income of 325,390,298 contributed positively to equity growth.
- Dividend payments of 98,135,972 reduced retained earnings.
- Share repurchases of 30,020,576 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥325.39 Million | +8.18% |
| Dividends Paid | CN¥98.14 Million | -2.47% |
| Share Repurchases | CN¥30.02 Million | -0.75% |
| Other Changes | CN¥11.22 Million | +0.28% |
| Total Change | CN¥- | 5.53% |
Book Value vs Market Value Analysis
This analysis compares Sichuan Huiyu Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.89x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥-0.51 | CN¥17.77 | x |
| 2018-12-31 | CN¥-0.42 | CN¥17.77 | x |
| 2019-12-31 | CN¥0.96 | CN¥17.77 | x |
| 2020-12-31 | CN¥1.77 | CN¥17.77 | x |
| 2021-12-31 | CN¥8.40 | CN¥17.77 | x |
| 2022-12-31 | CN¥8.78 | CN¥17.77 | x |
| 2023-12-31 | CN¥8.90 | CN¥17.77 | x |
| 2024-12-31 | CN¥9.42 | CN¥17.77 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sichuan Huiyu Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 8.18%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 29.73%
- • Asset Turnover: 0.21x
- • Equity Multiplier: 1.30x
- Recent ROE (8.18%) is below the historical average (15.01%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -605.83% | 0.06x | 0.00x | CN¥-66.19 Million |
| 2018 | 0.00% | -40.51% | 0.16x | 0.00x | CN¥-6.93 Million |
| 2019 | 43.30% | 25.02% | 0.82x | 2.10x | CN¥136.08 Million |
| 2020 | 45.69% | 25.17% | 1.12x | 1.61x | CN¥268.18 Million |
| 2021 | 12.53% | 24.45% | 0.44x | 1.16x | CN¥90.01 Million |
| 2022 | 6.70% | 16.67% | 0.35x | 1.15x | CN¥-122.82 Million |
| 2023 | 3.71% | 15.08% | 0.20x | 1.24x | CN¥-237.27 Million |
| 2024 | 8.18% | 29.73% | 0.21x | 1.30x | CN¥-72.51 Million |
Industry Comparison
This section compares Sichuan Huiyu Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sichuan Huiyu Pharmaceutical Co Ltd (688553) | CN¥3.72 Billion | 0.00% | 0.31x | $514.70 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |